High-risk human papillomavirus targets crossroads in immune signaling

Viruses

Volumn 7, Issue 5, 2015, Pages 2485-2506

  Tummers, Bart ^a   van der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

High risk human papillomavirus; Immune evasion; Keratinocyte

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; INFLAMMASOME; INTERFERON REGULATORY FACTOR; MEMBRANE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CROSS PRESENTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNITY; INNATE IMMUNITY; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WART VIRUS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; PAPILLOMAVIRIDAE; PHYSIOLOGY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; KERATINOCYTES; PAPILLOMAVIRIDAE; SIGNAL TRANSDUCTION;

EID: 84930938913     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7052485     Document Type: Review

References (103)

1. Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342-350. [CrossRef] [PubMed]
2. Cubie, H.A. Diseases associated with human papillomavirus infection. Virology 2013,445, 21-34.
3. De Villiers, E.M.; Fauquet, C.; Broker, T.R.; Bernard, H.U.; zur Hausen, H. Classification of papillomaviruses. Virology 2004, 324, 17-27. [CrossRef] [PubMed]
4. Akgul, B.; Cooke, J.C.; Storey, A. HPV-associated skin disease. J. Pathol. 2006, 208, 165-175.
5. Veldhuijzen, N.J.; Snijders, P.J.; Reiss, P.; Meijer, C.J.; van de Wijgert, J.H. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect. Dis. 2010,10, 862-874.
6. Arbyn, M.; Anttila, A.; Jordan, J.; Ronco, G.; Schenck, U.; Segnan, N.; Wiener, H.; Herbert, A.; von Karsa, L. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-Summary document. Ann. Oncol. 2010, 21,448-458. [CrossRef] [PubMed]
7. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015,136, E359-E386. [CrossRef] [PubMed]
8. Munoz, N.; Bosch, F.X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527. [CrossRef] [PubMed]
9. Smith, J.S.; Lindsay, L.; Hoots, B.; Keys, J.; Franceschi, S.; Winer, R.; Clifford, G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer 2007,121, 621-632. [CrossRef] [PubMed]
10. Sapp, M.; Bienkowska-Haba, M. Viral entry mechanisms: Human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 2009, 276, 7206-7216.
11. Doorbar, J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32 (Suppl. 1), S7-S15.
12. Bedell, M.A.; Hudson, J.B.; Golub, T.R.; Turyk, M.E.; Hosken, M.; Wilbanks, G.D.; Laimins, L.A. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 1991, 65, 2254-2260. [PubMed]
13. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 2006,110, 525-541. [CrossRef] [PubMed]
14. Lou, Z.; Wang, S. E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis. J. Int. Med. Res. 2014, 42, 247-260. [CrossRef] [PubMed]
15. Van der Burg, S.H.; Melief, C.J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 2011, 23, 252-257. [CrossRef] [PubMed]
16. Nestle, F.O.; Di Meglio, P.; Qin, J.Z.; Nickoloff, B.J. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009, 9, 679-691. [PubMed]
17. Karim, R.; Tummers, B.; Meyers, C; Biryukov, J.L.; Alam, S.; Backendorf, C; Jha, V.; Offringa, R.; van Ommen, G.J.; Melief, C.J. et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLOS Pathog. 2013, 9, e1003384. [CrossRef] [PubMed]
18. Karim, R.; Meyers, C.; Backendorf, C.; Ludigs, K.; Offringa, R.; van Ommen, G.J.; Melief, C.J.; van der Burg, S.H.; Boer, J.M. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLOS ONE 2011, 6, e17848.
19. Reinholz, M.; Kawakami, Y.; Salzer, S.; Kreuter, A.; Dombrowski, Y.; Koglin, S.; Kresse, S.; Ruzicka, T.; Schauber, J. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch. Dermatol. Res. 2013, 305, 723-732. [CrossRef] [PubMed]
20. Kalali, B.N.; Kollisch, G.; Mages, J.; Muller, T.; Bauer, S.; Wagner, H.; Ring, J.; Lang, R.; Mempel, M.; Ollert, M. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J. Immunol. 2008,181, 2694-2704. [CrossRef] [PubMed]
21. Hasan, U.A.; Bates, E.; Takeshita, F.; Biliato, A.; Accardi, R.; Bouvard, V.; Mansour, M.; Vincent, I.; Gissmann, L.; Iftner, T. et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 2007,178, 3186-3197.
22. Reiser, J.; Hurst, J.; Voges, M.; Krauss, P.; Munch, P.; Iftner, T.; Stubenrauch, F. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 2011, 85, 11372-11380.
23. Hasan, U.A.; Zannetti, C.; Parroche, P.; Goutagny, N.; Malfroy, M.; Roblot, G.; Carreira, C.; Hussain, I.; Muller, M.; Taylor-Papadimitriou, J. et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 2013, 210, 1369-1387. [CrossRef] [PubMed]
24. Andersen, J.M.; Al-Khairy, D.; Ingalls, R.R. Innate immunity at the mucosal surface: Role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol. Reprod. 2006, 74, 824-831. [CrossRef] [PubMed]
25. Le Bon, A.; Tough, D.F. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 2002, 14, 432-436. [CrossRef] [PubMed]
26. McNab, F.; Mayer-Barber, K.; Sher, A.; Wack, A.; O'Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 2015,15, 87-103. [CrossRef] [PubMed]
27. O'Neill, L.A.; Golenbock, D.; Bowie, A.G. The history of Toll-like receptors-Redefining innate immunity. Nat. Rev. Immunol. 2013, 13, 453-460. [CrossRef] [PubMed]
28. Chang, Y.E.; Laimins, L.A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 2000, 74, 4174-4182.
29. Karstensen, B.; Poppelreuther, S.; Bonin, M.; Walter, M.; Iftner, T.; Stubenrauch, F. Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology 2006, 353, 200-209. [CrossRef] [PubMed]
30. Nees, M.; Geoghegan, J.M.; Hyman, T.; Frank, S.; Miller, L.; Woodworth, CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 2001, 75, 4283-4296. [CrossRef] [PubMed]
31. Sunthamala, N.; Thierry, F.; Teissier, S.; Pientong, C.; Kongyingyoes, B.; Tangsiriwatthana, T.; Sangkomkamhang, U.; Ekalaksananan, T. E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-kappa transcription in keratinocytes. PLOS One 2014, 9, e91473. [CrossRef] [PubMed]
32. Rincon-Orozco, B.; Halec, G.; Rosenberger, S.; Muschik, D.; Nindl, I.; Bachmann, A.; Ritter, T.M.; Dondog, B.; Ly, R.; Bosch, F.X. et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 2009, 69, 8718-8725.
33. Ronco, L.V.; Karpova, A.Y.; Vidal, M.; Howley, P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12, 2061-2072. [CrossRef] [PubMed]
34. Park, J.S.; Kim, E.J.; Kwon, H.J.; Hwang, E.S.; Namkoong, S.E.; Um, S.J. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 2000, 275, 6764-6769. [CrossRef] [PubMed]
35. Perea, S.E.; Massimi, P.; Banks, L. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int. J. Mol. Med. 2000, 5, 661-666. [PubMed]
36. Muto, V.; Stellacci, E.; Lamberti, A.G.; Perrotti, E.; Carrabba, A.; Matera, G.; Sgarbanti, M.; Battistini, A.; Liberto, M.C.; Foca, A. Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes. J. Virol. 2011, 85, 5070-5080. [CrossRef] [PubMed]
37. Ivashkiv, L.B.; Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14, 36-49. [CrossRef] [PubMed]
38. Li, S.; Labrecque, S.; Gauzzi, M.C.; Cuddihy, A.R.; Wong, A.H.; Pellegrini, S.; Matlashewski, G.J.; Koromilas, A.E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18, 5727-5737. [CrossRef] [PubMed]
39. Hong, S.; Mehta, K.P.; Laimins, L.A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 2011, 85, 9486-9494. [CrossRef] [PubMed]
40. Barnard, P.; McMillan, N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259, 305-313. [CrossRef] [PubMed]
41. Barnard, P.; Payne, E.; McMillan, N.A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000, 277, 411-419.
42. Oeckinghaus, A.; Hayden, M.S.; Ghosh, S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12, 695-708. [CrossRef] [PubMed]
43. Havard, L.; Delvenne, P.; Frare, P.; Boniver, J.; Giannini, S.L. Differentialproductionofcytokines and activation of NF-kappaB in HPV-transformed keratinocytes. Virology 2002, 298, 271-285.
44. Havard, L.; Rahmouni, S.; Boniver, J.; Delvenne, P. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: Role of E6 and E7 oncoproteins. Virology 2005, 331, 357-366. [CrossRef] [PubMed]
45. Prabhavathy, D.; Prabhakar, B.N.; Karunagaran, D. HPV16 E2-mediated potentiation of NF-kappaB activation induced by TNF-alpha involves parallel activation of STAT3 with a reduction in E2-induced apoptosis. Mol. Cell. Biochem. 2014, 394, 77-90. [CrossRef] [PubMed]
46. Vancurova, I.; Wu, R.; Miskolci, V.; Sun, S. Increased p50/p50 NF-kappaB activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J. Virol. 2002, 76, 1533-1536. [CrossRef] [PubMed]
47. Takami, Y.; Nakagami, H.; Morishita, R.; Katsuya, T.; Cui, T.X.; Ichikawa, T.; Saito, Y.; Hayashi, H.; Kikuchi, Y.; Nishikawa, T. et al. Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kappaB activation. Arterioscler. Thromb. Vase Biol. 2007, 27, 2184-2190. [CrossRef] [PubMed]
48. Spitkovsky, D.; Hehner, S.P.; Hofmann, T.G.; Moller, A.; Schmitz, M.L. The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J. Biol. Chem. 2002, 277, 25576-25582. [CrossRef] [PubMed]
49. Patel, D.; Huang, S.M.; Baglia, L.A.; McCance, D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999,18, 5061-5072.
50. Zimmermann, H.; Degenkolbe, R.; Bernard, H.U.; O'Connor, M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 1999, 73, 6209-6219. [PubMed]
51. Huang, S.M.; McCance, D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 2002, 76, 8710-8721. [CrossRef] [PubMed]
52. Bernat, A.; Avvakumov, N.; Mymryk, J.S.; Banks, L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003,22,7871-7881. [CrossRef] [PubMed]
53. Lee, D.; Lee, B.; Kim, J.; Kim, D.W.; Choe, J. cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J. Biol. Chem. 2000, 275,7045-7051. [CrossRef] [PubMed]
54. Marcello, A.; Massimi, P.; Banks, L.; Giacca, M. Adeno-associated virus type 2 rep protein inhibits human papillomavirus type 16 E2 recruitment of the transcriptional coactivator p300. J. Virol. 2000, 74, 9090-9098. [CrossRef] [PubMed]
55. Akerman, G.S.; Tolleson, W.H.; Brown, K.L.; Zyzak, L.L.; Mourateva, E.; Engin, T.S.; Basaraba, A.; Coker, A.L.; Creek, K.E.; Pirisi, L. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 2001, 61, 3837-3843. [PubMed]
56. Tummers, B.; Goedemans, R.; Pelascini, L.P.L.; Jordanova, E.S.; van Esch, E.M.G.; Meyers, C.; Melief, C.J.M.; Boer, J.M.; van der Burg, S.H. The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFkB activation. Nat. Commun. 2015, 6, 6537.
57. Kim, S.H.; Juhnn, Y.S.; Kang, S.; Park, S.W.; Sung, M.W.; Bang, Y.J.; Song, Y.S. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci. 2006, 63, 930-938. [CrossRef] [PubMed]
58. Spangle, J.M.; Munger, K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLOS Pathog. 2013, 9, e1003237. [CrossRef] [PubMed]
59. Zhang, B.; Srirangam, A.; Potter, D.A.; Roman, A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005, 24, 2585-2588. [CrossRef] [PubMed]
60. Kalinowski, A.; Ueki, I.; Min-Oo, G.; Ballon-Landa, E.; Knoff, D.; Galen, B.; Lanier, L.L.; Nadel, J.A.; Koff, J.L. EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production. Am.. J. Physiol. Lung Cell. Mol. Physiol. 2014, 307, L186-L196. [CrossRef] [PubMed]
61. Mascia, F.; Mariani, V.; Girolomoni, G.; Pastore, S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 2003,163, 303-312. [CrossRef] [PubMed]
62. Paul, T.; Schumann, C.; Rudiger, S.; Boeck, S.; Heinemann, V.; Kachele, V.; Steffens, M.; Scholl, C.; Hichert, V.; Seufferlein, T. et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur. J. Cancer 2014, 50, 1855-1863. [CrossRef] [PubMed]
63. Niebler, M.; Qian, X.; Hofler, D.; Kogosov, V.; Kaewprag, J.; Kaufmann, A.M.; Ly, R.; Bohmer, G.; Zawatzky, R.; Rosl, F. et al. Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: A novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLOS Pathog. 2013, 9, e1003536. [CrossRef] [PubMed]
64. Van der Burg, S.H.; Arens, R.; Melief, C.J. Immunotherapy for persistent viral infections and associated disease. Trends Immunol. 2011, 32, 97-103. [CrossRef] [PubMed]
65. Filippova, M.; Song, H.; Connolly, J.L.; Dermody, T.S.; Duerksen-Hughes, P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 2002, 277, 21730-21739. [CrossRef] [PubMed]
66. Filippova, M.; Parkhurst, L.; Duerksen-Hughes, P.J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 2004, 279, 25729-25744. [CrossRef] [PubMed]
67. Boulabiar, M.; Boubaker, S.; Favre, M.; Demeret, C. Keratinocyte sensitization to tumour necrosis factor-induced nuclear factor kappa B activation by the E2 regulatory protein of human papillomaviruses. J. Gen. Virol. 2011, 92, 2422-2427. [CrossRef] [PubMed]
68. Tummers, B.; van Esch, E.M.; Ma, W.; Goedemans, R.; Pelascini, L.P.L.; Vilarrasa-Blasi, R.; Torreggiani, S.; Meyers, C.; Melief, C.J.M.; Boer, J.M. et al. Human papillomavirus (HPV) down regulates the expression of IFITM1 to resist the anti-proliferative effects of IFNy and TNFa. 2015. submitted.
69. Spardy, N.; Covella, K.; Cha, E.; Hoskins, E.E.; Wells, S.I.; Duensing, A.; Duensing, S. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 2009, 69, 7022-7029. [CrossRef] [PubMed]
70. Fukushima, H.; Matsumoto, A.; Inuzuka, H.; Zhai, B.; Lau, A.W.; Wan, L.; Gao, D.; Shaik, S.; Yuan, M.; Gygi, S.P et al. SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep. 2012,1,434-443. [CrossRef] [PubMed]
71. Galy, A.H.; Spits, H. CD40 is functionally expressed on human thymic epithelial cells. J. Immunol. 1992, 149, 775-782. [PubMed]
72. Tummers, B.; Goedemans, R.; Jha, V.; Meyers, C.; Melief, C.J.M.; van derBurg, S.H.; Boer, J.M. CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV. J. Investig. Dermatol. 2014,134, 2918-2927. [CrossRef] [PubMed]
73. Zhou, F.; Frazer, I.H.; Leggatt, G.R. Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis. Exp. Dermatol. 2009,18, 1053-1059. [CrossRef] [PubMed]
74. Campo, M.S.; Graham, S.V.; Cortese, M.S.; Ashrafi, G.H.; Araibi, E.H.; Dornan, E.S.; Miners, K.; Nunes, C.; Man, S. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 2010, 407, 137-142. [CrossRef] [PubMed]
75. Zhou, F.; Leggatt, G.R.; Frazer, I.H. Human papillomavirus 16 E7 protein inhibits interferon-gamma-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBSJ. 2011, 278, 955-963. [CrossRef] [PubMed]
76. Georgopoulos, N.T.; Proffitt, J.L.; Blair, G.E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000, 19, 4930-4935. [CrossRef] [PubMed]
77. Heller, C.; Weisser, T.; Mueller-Schickert, A.; Rufer, E.; Hoh, A.; Leonhardt, R.M.; Knittler, M.R. Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression. J. Biol. Chem. 2011, 286, 10983-10997. [CrossRef] [PubMed]
78. Li, H.; Ou, X.; Xiong, J.; Wang, T. HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem. Biophys. Res. Commun. 2006, 349, 1315-1321. [CrossRef] [PubMed]
79. Li, H.; Zhan, T.; Li, C.; Liu, M.; Wang, Q.K. Repression of MHC class I transcription by HPV16E7 through interaction with a putative RXRbeta motif and NF-kappaB cytoplasmic sequestration. Biochem. Biophys. Res. Commun. 2009, 388, 383-388. [CrossRef] [PubMed]
80. Ashrafi, G.H.; Haghshenas, M.R.; Marchetti, B.; O'Brien, P.M.; Campo, M.S. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 2005, 113, 276-283. [CrossRef] [PubMed]
81. Zhou, F.; Chen, J.; Zhao, K.N. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J. Gen. Virol. 2013, 94, 2504-2514. [CrossRef] [PubMed]
82. Cortese, M.S.; Ashrafi, G.H.; Campo, M.S. All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization. Int. J. Cancer 2010, 126, 1675-1682. [PubMed]
83. Ashrafi, G.H.; Haghshenas, M.; Marchetti, B.; Campo, M.S. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 2006,119, 2105-2112. [CrossRef] [PubMed]
84. Gruener, M.; Bravo, I.G.; Momburg, F.; Alonso, A.; Tomakidi, P. The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol. J. 2007,4, e11. [CrossRef]
85. Miura, S.; Kawana, K.; Schust, D.J.; Fujii, T.; Yokoyama, T.; Iwasawa, Y.; Nagamatsu, T.; Adachi, K.; Tomio, A.; Tomio, K. et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: A possible mechanism for immune evasion by HPV. J. Virol. 2010, 84, 11614-11623. [CrossRef] [PubMed]
86. Regan, J.A.; Laimins, L.A. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 2008, 82, 10042-10051. [CrossRef] [PubMed]
87. Abe, F.; van Prooyen, N.; Ladasky, J.J.; Edidin, M. Interaction of Bap31 and MHC class I molecules and their traffic out of the endoplasmic reticulum. J. Immunol. 2009,182, 4776-4783. [CrossRef] [PubMed]
88. Zhang, B.; Li, P.; Wang, E.; Brahmi, Z.; Dunn, K.W.; Blum, J.S.; Roman, A. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 2003,310,100-108. [CrossRef] [PubMed]
89. Straight, S.W.; Herman, B.; McCance, D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69, 3185-3192. [PubMed]
90. Thomsen, P.; van Deurs, B.; Norrild, B.; Kayser, L. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene 2000,19, 6023-6032. [CrossRef] [PubMed]
91. Chang, Y.E.; Pena, L.; Sen, G.C.; Park, J.K.; Laimins, L.A. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 2002, 76, 8864-8874. [CrossRef] [PubMed]
92. Herdman, M.T.; Pett, M.R.; Roberts, I.; Alazawi, W.O.; Teschendorff, A.E.; Zhang, X.Y.; Stanley, M.A.; Coleman, N. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006, 27, 2341-2353. [CrossRef] [PubMed]
93. Terenzi, F.; Saikia, P.; Sen, G.C. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J. 2008, 27, 3311-3321. [CrossRef] [PubMed]
94. Munoz-Fontela, C.; Macip, S.; Martinez-Sobrido, L.; Brown, L.; Ashour, J.; Garcia-Sastre, A.; Lee, S.W.; Aaronson, S.A. Transcriptional role of p53 in interferon-mediated antiviral immunity. J. Exp. Med. 2008, 205, 1929-1938. [CrossRef] [PubMed]
95. Munoz-Fontela, C; Pazos, M.; Delgado, I.; Murk, W.; Mungamuri, S.K.; Lee, S.W.; Garcia-Sastre, A.; Moran, T.M.; Aaronson, S.A. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J. Immunol. 2011,187, 6428-6436. [CrossRef] [PubMed]
96. Branca, M.; Giorgi, C.; Ciotti, M.; Santini, D.; di Bonito, L.; Costa, S.; Benedetto, A.; Bonifacio, D.; Di Bonito, P.; Paba, P. et al. Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer. Diagn. Cytopathol. 2006, 34, 555-563. [CrossRef] [PubMed]
97. Xu, M.; Katzenellenbogen, R.A.; Grandori, C.; Galloway, D.A. NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J. Virol. 2010, 84, 11461-11469. [CrossRef] [PubMed]
98. An, J.; Mo, D.; Liu, H.; Veena, M.S.; Srivatsan, E.S.; Massoumi, R.; Rettig, M.B. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 2008,14, 394-407. [CrossRef] [PubMed]
99. Vandermark, E.R.; Deluca, K.A.; Gardner, C.R.; Marker, D.F.; Schreiner, C.N.; Strickland, D.A.; Wilton, K.M.; Mondal, S.; Woodworth, C.D. Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology 2012, 425, 53-60. [CrossRef] [PubMed]
100. Magnusson, P.K.; Lichtenstein, P.; Gyllensten, U.B. Heritability of cervical tumours. Int. J. Cancer 2000, 88, 698-701. [CrossRef] [PubMed]
101. Mehta, A.M.; Jordanova, E.S.; van Wezel, T.; Uh, H.W.; Corver, W.E.; Kwappenberg, K.M.; Verduijn, W.; Kenter, G.G.; van der Burg, S.H.; Fleuren, G.J. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosom. Cancer 2007, 46, 577-586. [CrossRef] [PubMed]
102. Wang, S.S.; Bratti, M.C.; Rodriguez, A.C.; Herrero, R.; Burk, R.D.; Porras, C.; Gonzalez, P.; Sherman, M.E.; Wacholder, S.; Lan, Z.E. et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 2009,199, 20-30. [CrossRef] [PubMed]
103. Bodelon, C.; Madeleine, M.M.; Johnson, L.G.; Du, Q.; Galloway, D.A.; Malkki, M.; Petersdorf, E.W.; Schwartz, S.M. Genetic variation in the TLR and NF-kappaB pathways and cervical and vulvar cancer risk: A population-based case-control study. Int. J. Cancer 2014,134, 437-444. [CrossRef] [PubMed]